28 AUGUST 2026

ASX RELEASE

RESULTS OF ANNUAL GENERAL MEETING

Melbourne, Australia: Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), ("Amplia" or the "Company"), is pleased to confirm that each of the resolutions put to its Annual General Meeting held earlier today were carried. Details of the results of the meeting are attached.

This ASX announcement was approved and authorised for release by the Company Secretary.

Investor Contact:
Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

Media Contact:
H^CK Director, Haley Chartres
haley@hck.digital
+61 411 235 692

U.S. Contact:
Robert Giordano
rjgiordano@ggrouplifesciences.com
+1 917 327 3938

U.S. Media:
media@ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on X (@ampliatx) and LinkedIn.

About Narmafotinib

Narmafotinib (AMP945) is the company's best-in-class inhibitor of FAK, a protein over-expressed in multiple cancers and a drug target gaining increasing attention for its role in solid tumours. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. Narmafotinib is currently being investigated in the ACCENT trial in advanced pancreatic cancer where it is dosed in combination with the chemotherapies gemcitabine and nab-paclitaxel (Abraxane®) in first-line patients. The trial has achieved its desired outcome in achieving a response rate of 36%, superior to chemotherapy alone as reported for the benchmark MPACT study. A median Overall Survival (mOS) of 11.1 months has been reported along with an unprecedented complete response rate of 7.8%. A second trial (AMPLICITY) is being run at sites in Australia investigating the combination of narmafotinib with the chemotherapy mFOLFIRINOX in advanced pancreatic cancer patients, and a third trial in ovarian cancer (the PRROSE trial) is scheduled to begin recruiting later this year.

AMPLIA THERAPEUTICS LIMITED
Annual General Meeting
Friday, 28 August 2026
Results of Meeting

computershare

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Remuneration Report	Ordinary	126,375,475 99.10%	349,736 0.27%	804,422 0.63%	1,700	128,044,955 99.73%	349,736 0.27%	1,700	Carried
2 Re-elect Dr Robert Peach as a Director of the Company	Ordinary	138,658,888 99.59%	32,421 0.02%	539,722 0.39%	6,136,864	140,063,668 99.98%	32,421 0.02%	6,136,864	Carried
3 Elect Mr Brett Carter as a Director of the Company	Ordinary	144,708,232 99.55%	114,241 0.08%	539,722 0.37%	5,700	146,113,012 99.92%	114,241 0.08%	5,700	Carried
4 Approval for extra 10% Placement Facility	Special	112,106,202 77.14%	32,704,132 22.50%	514,722 0.36%	42,839	113,485,982 77.63%	32,704,132 22.37%	42,839	Carried
5 Increase in Non-Executive Directors' Fee Pool	Special	125,942,426 98.98%	782,485 0.61%	514,722 0.41%	13,848,688	127,254,636 99.34%	850,055 0.66%	13,848,688	Carried
6 Proposed Issue of Zero Exercise Price Options to Dr Christopher Burns (Managing Director and Chief Executive Officer)	Ordinary	132,204,147 99.05%	745,928 0.56%	514,722 0.39%	11,903,098	133,583,927 99.44%	745,928 0.56%	11,903,098	Carried
7 Proposed Issue of Zero Exercise Price Options to Ms Jane Bell (Non Executive Chair)	Ordinary	133,368,072 98.74%	1,194,877 0.88%	514,722 0.38%	10,287,524	134,747,852 99.12%	1,194,877 0.88%	10,287,524	Carried
8 Proposed Issue of Zero Exercise Price Options to Dr Robert Peach (Non Executive Director)	Ordinary	127,236,908 98.67%	1,194,877 0.93%	514,722 0.40%	16,418,688	128,616,688 99.08%	1,194,877 0.92%	16,418,688	Carried
9 Proposed Issue of Zero Exercise Price Options to Dr Warwick Tong (Non Executive Director)	Ordinary	132,814,263 98.33%	1,194,877 0.88%	1,068,531 0.79%	10,287,524	134,747,852 99.12%	1,194,877 0.88%	10,287,524	Carried
10 Proposed Issue of Zero Exercise Price Options to Mr Brett Carter (Non Executive Director)	Ordinary	133,385,572 98.75%	1,177,377 0.87%	514,722 0.38%	10,287,524	134,765,352 99.13%	1,177,377 0.87%	10,287,524	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.